Evidence map›Paper›PMID 34708338›Full record

Trial reportIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2021

Role of Helicobacter pylori eradication in patients with functional dyspepsia.

Prateek Padole, Piyush Ranjan, Munish Sachdeva, Mandhir Kumar

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04697641 (Efficacy of Helicobacter Pylori Eradication on Symptoms of Functional Dyspepsia - A Randomised Controlled Trial), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04697641 nacompletednot on this map

Efficacy of Helicobacter Pylori Eradication on Symptoms of Functional Dyspepsia - A Randomised Controlled Trial

TypeinterventionalSponsorSir Ganga Ram HospitalRan2017 to 2019Enrolled202ConditionsDyspepsia, Helicobacter Pylori InfectionArmsClarithromycin 500mg, Amoxicillin 1000 MG, Pantoprazole 40mg, Levosulpiride, Acotiamide
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Concomitant and Bismuth Quadruple Therapy forAntibiotics (Basel, Switzerland) · 2024
    Article
  2. Choosing optimum regimen for treating Helicobacter pylori infection: Regional data may be the quintessential guide.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Article
  3. Review
  4. Editorial commentary on Indian Journal of Gastroenterology-September-October 2021.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Prateek PadoleInstitute of Liver, Gastroenterology and Pancreaticobiliary Sciences, Sir Ganga Ram Hospital, New Delhi , 110 060, India.
Piyush RanjanInstitute of Liver, Gastroenterology and Pancreaticobiliary Sciences, Sir Ganga Ram Hospital, New Delhi , 110 060, India. piyushranjan70@gmail.com.
Munish SachdevaInstitute of Liver, Gastroenterology and Pancreaticobiliary Sciences, Sir Ganga Ram Hospital, New Delhi , 110 060, India.
Mandhir KumarInstitute of Liver, Gastroenterology and Pancreaticobiliary Sciences, Sir Ganga Ram Hospital, New Delhi , 110 060, India.
Sir Ganga Ram Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelicobacter pylori (H. pylori) is implicated in the pathogenesis of functional dyspepsia (FD). There is conflicting data regarding the benefit of H. pylori eradication for symptom relief in FD.

aimsTo study the benefit of eradicating H. pylori in patients with FD as compared to standard medical treatment (SMT). Secondary aims were to find efficacy of H. pylori eradication therapy, recurrence of H. pylori after eradication, and predictors of efficacy.

methodsConsecutive adult patients of FD (ROME IV) with H. pylori infection presenting in the outpatient department of our hospital were enrolled. Patients with Global Overall Symptom (GOS) scale > 2 and H. pylori infection were included. Patients were randomized into two groups: group 1 received H. pylori eradication therapy and group 2 received SMT. Treatment success was defined as symptom relief (GOS score < 2 and reduction by at least 2 points at 6 months) and H. pylori eradication was defined as stool antigen negative at 4 weeks.

resultsOf 329 participants with FD, 253 were H. pylori positive (rapid urease test and stool antigen test) (76.89%). After exclusions, 202 were randomized into two groups of 101 each. Thirty-two patients in group 1 and 31 in group 2 had treatment success (31.7% vs. 30.7%, p=1.000). The efficacy of H. pylori eradication therapy was 74.46% (70/94). H. pylori reinfection rate was 26.02% (19/73).

conclusionsH. pylori eradication therapy does not provide additional benefit in symptom relief in patients with FD as compared with SMT.

trial registrationNCT04697641 (retrospectively registered on www.clinicaltrials.gov in January 2021).

Indexed as

DyspepsiaHelicobacter InfectionsHelicobacter pyloriAdultAnti-Bacterial AgentsDrug Therapy, CombinationHumansTreatment OutcomeAnti-Bacterial AgentsEpigastric pain syndromeFunctional dyspepsiaGOS scaleH. pylori eradication therapyLikert scaleNon-ulcer dyspepsiaPostprandial distress syndromeRapid urease testRome IV criteriaStool antigen testTriple therapy

Identifiers

PMID34708338
OpenAlexW3208563553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.